Oncolytic Adenovirus Market Report 2026

Oncolytic Adenovirus Market Overview

• Oncolytic Adenovirus market size has reached to $132.49 billion in 2025 • Expected to grow to $195.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Surge In Cancer Diagnoses Drives Breakthroughs In Precision Treatment Technologies • Market Trend: VCN-01 A New Frontier In Cancer Treatment With FDA Fast Track Approval • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oncolytic Adenovirus Market?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body's anti-tumor response. The main virus types of oncolytic adenoviruses are adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other virus types. Adenovirus type 5-based oncolytic viruses are genetically modified adenoviruses designed to selectively infect and destroy cancer cells while sparing normal tissues. These are applied in treating melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and others and are used by end-users including hospitals, cancer research institutes, biotechnology companies, and academic and research institutes.

What Is The Oncolytic Adenovirus Market Growth Forecast?

The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $195.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for engineered adenovirus therapies, increasing adoption in breast, ovarian, and lung cancers, growth in biotechnology company participation, rising funding for clinical trials and R&D, expansion of hospital and research institute capabilities in gene therapy. Major trends in the forecast period include rising adoption of ai and big data in oncolytic virus research, increasing application of genomics and precision medicine in virus engineering, growing use of digital platforms for clinical trial monitoring, rising automation in viral production and quality control, increasing iot-enabled monitoring of virus storage and distribution.

Global Oncolytic Adenovirus Market Segmentation

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types 2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications 3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes Subsegments: 1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based 2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based 3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

What Are The Drivers Of The Oncolytic Adenovirus Market?

The increasing incidence of cancer is expected to propel the growth of the oncolytic adenovirus market going forward. Cancer is a disease characterized by uncontrolled cell growth and spread to other parts of the body. The increasing incidence of cancer is driven by aging populations, lifestyle factors, environmental exposures, genetic predispositions, and improved detection. Oncolytic adenovirus targets and kills cancer cells selectively, offering a promising approach to treating the increasing incidence of cancer. For instance, in May 2024, according to the reports published by the National Cancer Institute (NCI), a US-based government agency, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Furthermore, in 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, 1.8% of Australians had cancer, with males (2.1%) slightly more affected than females (1.6%), especially those aged 75 and over. Therefore, the increasing incidence of cancer is driving growth in the oncolytic adenovirus industry. The growing adoption of personalized medicine is expected to propel the growth of the oncolytic adenovirus market going forward. Personalized medicine refers to tailoring treatments to individual patients based on their genetic, biomarker, phenotypic, or psychosocial characteristics to maximize efficacy and minimize toxicity. The growing adoption of personalized medicine is driven by advances in understanding tumor biology and the ability to design therapies that target specific genetic mutations or biomarkers, improving treatment outcomes and patient safety. Oncolytic adenoviruses benefit from this approach by enabling highly targeted viral therapies that selectively infect and kill cancer cells. For instance, in February 2024, according to the Personalized Medicine Coalition, 26 new personalized treatments were approved by the U.S. FDA in 2023, including 20 new molecular entities and 6 gene or cell‑based therapies. Therefore, growing adoption of personalized medicine is driving the growth of the oncolytic adenovirus industry.

Key Players In The Global Oncolytic Adenovirus Market

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Global Oncolytic Adenovirus Market Trends and Insights

Major companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which combines oncolytic virotherapy with chemotherapy to improve tumor targeting and enhance therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also enhancing the effectiveness of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 when used in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and replicates within tumor cells, helping to break down the tumor stroma, a key obstacle to effective cancer treatment.

Regional Outlook

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oncolytic Adenovirus Market?

The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oncolytic Adenovirus Market Report 2026?

The oncolytic adenovirus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.